| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
PBR (peripheral benzodiazepine receptor) / TSPO (translocator protein, 18 kDa). DAA1106 is a potent and selective agonist for PBR with an IC50 of 0.21 nM in displacing [3H]Ro5-4864. It has a sub-nanomolar binding affinity (Ki) of 0.28 nM. The compound has no affinity for the GABAA receptor.
|
|---|---|
| ln Vitro |
DAA1106 binding to PBR was significantly increased in widespread areas in mild cognitive impairment (MCI) subjects when compared to healthy controls. It acts as a potent and selective agonist at the peripheral benzodiazepine receptor. The compound has been used extensively in its radiolabelled form to map TSPO in the body and brain.
|
| ln Vivo |
DAA1106 exhibits anxiolytic-like effects in animal models. It has been used extensively in its 3H or 11C radiolabelled form to map TSPO in the body and brain, which has been especially helpful in monitoring the progress of neurodegenerative diseases such as Alzheimer's disease.
|
| Enzyme Assay |
DAA1106 is evaluated in cell-free receptor binding assays using membrane preparations expressing PBR/TSPO. Radioligand binding displacement assays are performed to determine the affinity (IC50 and Ki) of DAA1106 for PBR. Competition binding experiments are conducted with increasing concentrations of DAA1106 and a fixed concentration of [3H]Ro5-4864.
|
| Cell Assay |
DAA1106 is assessed in cell-based assays using cells expressing PBR/TSPO. Radioligand binding studies are performed to evaluate the compound's affinity and selectivity for PBR. The compound shows no affinity for the GABAA receptor. Binding to PBR is measured using radiolabelled DAA1106 or competitive binding with [3H]Ro5-4864.
|
| Animal Protocol |
DAA1106 is administered in animal models to evaluate its anxiolytic effects and TSPO binding. It has been used extensively in its radiolabelled form to map TSPO in the body and brain. The compound is used in imaging studies to monitor the progress of neurodegenerative diseases such as Alzheimer's disease.
|
| ADME/Pharmacokinetics |
DAA1106 has a molecular weight of 395.42 and a molecular formula of C23H22FNO4. It is soluble in DMSO at 79 mg/mL (199.78 mM) and in ethanol at 40 mg/mL. It is insoluble in water. The compound should be stored as a powder at -20°C for up to 3 years. In vivo, it can be formulated as a homogeneous suspension in CMC-Na at ≥5 mg/mL or as a clear solution in 5% DMSO, 40% PEG300, 5% Tween 80, and 50% ddH2O.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is available for DAA1106. The compound is for research use only and is not intended for human therapeutic use. It has been used extensively in radiolabelled form for imaging studies. The compound exhibits anxiolytic-like effects in animal models.
|
| References | |
| Additional Infomation |
DAA1106 is a highly potent and selective agonist for the peripheral benzodiazepine receptor (PBR/TSPO) with an IC50 of 0.21 nM. It has no affinity for the GABAA receptor. The compound has a CAS number of 220551-92-8 and a molecular weight of 395.42. It has been used extensively in its radiolabelled form to map TSPO in the body and brain. The compound is for research use only and has not been approved for clinical use.
|
| Molecular Formula |
C23H22FNO4
|
|---|---|
| Molecular Weight |
395.4304
|
| Exact Mass |
395.153
|
| CAS # |
220551-92-8
|
| PubChem CID |
10430788
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.188
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
29
|
| Complexity |
513
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
DCRZYADKQRHHSF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H22FNO4/c1-16(26)25(15-17-13-20(27-2)10-12-22(17)28-3)21-14-18(24)9-11-23(21)29-19-7-5-4-6-8-19/h4-14H,15H2,1-3H3
|
| Chemical Name |
N-[(2,5-dimethoxyphenyl)methyl]-N-(5-fluoro-2-phenoxyphenyl)acetamide
|
| Synonyms |
DAA 1106; DAA-1106; DAA1106
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~252.90 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.32 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.32 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5289 mL | 12.6445 mL | 25.2889 mL | |
| 5 mM | 0.5058 mL | 2.5289 mL | 5.0578 mL | |
| 10 mM | 0.2529 mL | 1.2644 mL | 2.5289 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03117530 | Suspended | Drug: Minocycline | Autism Spectrum Disorder | University of California Los Angeles |
April 11, 2017 | Phase 1 |
| NCT03244592 | Withdrawn | Drug: Minocycline Drug: Sugar pill |
Alcohol Use Disorder
Inflammation Neurocognitive Dysfunction |
University of California Los Angeles |
January 15, 2018 | Phase 1 Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
